Scientific Participation at ARDD Meeting Focuses on Cellular Health

Cellular renewal Supplement

Natural autophagy activator

NEW YORK, NY, UNITED STATES, September 2, 2026 /EINPresswire.com/ -- Cellitas™ participated in the 12th Aging Research and Drug Discovery Meeting held August 25–29, 2025, where researchers, clinicians, and organizations examined aging biology, longevity medicine, and drug discovery. Chief Medical Officer Dr. Lucy Jones and Scientific Advisory Board member Professor Ghada Alsaleh represented the business.

Programming brought more than 200 speakers into discussions spanning Longevity Medicine, Emerging Science & Technologies, and Physics in Aging Biology. Nobel laureates Michael Levitt and Morten Meldal joined researchers from Stanford, Harvard Medical School, Buck Institute, Mayo Clinic, and the National Institute on Aging. Sessions also featured companies working across longevity research, placing academic and commercial perspectives within the same scientific program and related fields.

Representatives used the meeting to discuss Cellitas™’ polyamine-based approach to cellular health with members of the aging research community. Its work centers on autophagy, the body’s natural cellular renewal process, and on compounds such as spermidine, spermine, and arginine, which are studied for their roles in cellular maintenance.

Clinical evidence formed part of that scientific context. A published six-month randomized, controlled trial of the Cellitas™ formulation reported a 32% average increase in autophagy versus baseline, with no serious adverse events observed. Each batch is third-party tested, and certificates of analysis are published for purity and potency.

Research leadership also includes specialists whose work covers clinical trials, infection, immunity, healthy aging, autophagy, immune-cell function, and age-related changes in cellular regulation. Dr. Jones and Professor Alsaleh brought that background into conversations held across the meeting’s scientific program.

Cellitas™
Cellitas™
Info@Cellitas.com
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.